SG10201906239RA - Compositions and methods for inhibition of rna editing for treatment of cancer - Google Patents

Compositions and methods for inhibition of rna editing for treatment of cancer

Info

Publication number
SG10201906239RA
SG10201906239RA SG10201906239RA SG10201906239RA SG10201906239RA SG 10201906239R A SG10201906239R A SG 10201906239RA SG 10201906239R A SG10201906239R A SG 10201906239RA SG 10201906239R A SG10201906239R A SG 10201906239RA SG 10201906239R A SG10201906239R A SG 10201906239RA
Authority
SG
Singapore
Prior art keywords
inhibition
cancer
compositions
treatment
methods
Prior art date
Application number
SG10201906239RA
Inventor
Leilei Chen
Jin Tai Daryl Tay
Gang Chen
Original Assignee
Nat Univ Singapore
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore, Univ Nanyang Tech filed Critical Nat Univ Singapore
Priority to SG10201906239RA priority Critical patent/SG10201906239RA/en
Priority to US17/623,863 priority patent/US20220372475A1/en
Priority to EP20835003.3A priority patent/EP3994145A4/en
Priority to PCT/SG2020/050380 priority patent/WO2021002805A1/en
Priority to CN202080061907.2A priority patent/CN114531876A/en
Publication of SG10201906239RA publication Critical patent/SG10201906239RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
SG10201906239RA 2019-07-04 2019-07-04 Compositions and methods for inhibition of rna editing for treatment of cancer SG10201906239RA (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SG10201906239RA SG10201906239RA (en) 2019-07-04 2019-07-04 Compositions and methods for inhibition of rna editing for treatment of cancer
US17/623,863 US20220372475A1 (en) 2019-07-04 2020-07-03 Inhibitors Of RNA Editing And Uses Thereof
EP20835003.3A EP3994145A4 (en) 2019-07-04 2020-07-03 Inhibitors of rna editing and uses thereof
PCT/SG2020/050380 WO2021002805A1 (en) 2019-07-04 2020-07-03 Inhibitors of rna editing and uses thereof
CN202080061907.2A CN114531876A (en) 2019-07-04 2020-07-03 RNA editing inhibitors and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201906239RA SG10201906239RA (en) 2019-07-04 2019-07-04 Compositions and methods for inhibition of rna editing for treatment of cancer

Publications (1)

Publication Number Publication Date
SG10201906239RA true SG10201906239RA (en) 2021-02-25

Family

ID=74101373

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201906239RA SG10201906239RA (en) 2019-07-04 2019-07-04 Compositions and methods for inhibition of rna editing for treatment of cancer

Country Status (5)

Country Link
US (1) US20220372475A1 (en)
EP (1) EP3994145A4 (en)
CN (1) CN114531876A (en)
SG (1) SG10201906239RA (en)
WO (1) WO2021002805A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549076B (en) * 2021-07-23 2022-12-06 中国药科大学 Polysubstituted purine compound and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160762A1 (en) * 2004-12-13 2006-07-20 Children's Medical Center Corporation Methods for the treatment, diagnosis, and prognosis of cancer
CN109477103A (en) * 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ Single stranded RNA-editor's oligonucleotides
SG10201609048RA (en) * 2016-10-28 2018-05-30 Agency Science Tech & Res Antisense oligonucleotides

Also Published As

Publication number Publication date
EP3994145A1 (en) 2022-05-11
EP3994145A4 (en) 2023-12-06
US20220372475A1 (en) 2022-11-24
CN114531876A (en) 2022-05-24
WO2021002805A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
IL288914A (en) Compositions and methods for treating cancer
IL286350A (en) Compositions and methods for treating cancer
IL287982A (en) Compositions and methods for treating cancer
ZA202104870B (en) Methods and compositions for treating cancer
EP3965896A4 (en) Compositions and methods for treating cancer
EP4025590A4 (en) Methods and compositions for treating cancer
EP3723733A4 (en) Methods and compositions for treating cancer using exosomes-associated gene editing
EP4055040A4 (en) Compositions and methods for treatment of cancer with lekti
EP4003351A4 (en) Methods and compositions for treating cancer
IL289251A (en) Methods and compositions for treatment of pancreatic cancer
SG11202107017TA (en) Methods of treating cancer
IL288787A (en) Methods and compositions for improving outcomes of cancer patients
IL286153A (en) Methods and compositions for treating cancer
EP4110822A4 (en) Compositions and methods for treating cancer
EP4127722A4 (en) Methods and compositions for treating cancer
IL276203A (en) Compositions and methods of treating cancer
EP3983014A4 (en) Compositions and methods for treating cancer
SG10201906239RA (en) Compositions and methods for inhibition of rna editing for treatment of cancer
IL308766A (en) Compositions and methods for the treatment of prostate cancer
EP4051260A4 (en) Methods and compositions for treatment of cancer
IL289811A (en) Method of treating cancer
EP4114411A4 (en) Compositions and methods for the treatment of pancreatic cancer
EP4114864A4 (en) Compositions and methods for treatment of cancer
EP4077690A4 (en) Methods and compositions for treating cancer
EP3987032A4 (en) Methods and compositions for the treatment of cancer